EuCorVac-19

EuCorVac-19 is a vaccine developed for the prevention of COVID-19, a disease caused by the SARS-CoV-2 virus. The vaccine was developed by the European Union in collaboration with various pharmaceutical companies and research institutions.

Development

The development of EuCorVac-19 began in early 2020, following the outbreak of the COVID-19 pandemic. The vaccine was developed using a viral vector approach, which involves using a harmless virus to deliver a piece of the SARS-CoV-2 virus's genetic material into cells to stimulate an immune response.

Efficacy

Clinical trials of EuCorVac-19 have shown it to be effective in preventing COVID-19. The vaccine has been found to have an efficacy rate of over 90%, meaning it reduces the risk of developing COVID-19 by this amount in those who are vaccinated.

Safety

EuCorVac-19 has been found to be safe in clinical trials, with the most common side effects being mild and temporary, such as a sore arm, fatigue, and mild fever. Serious side effects are rare.

Distribution

The distribution of EuCorVac-19 is coordinated by the European Union, with priority given to high-risk groups such as healthcare workers, the elderly, and those with underlying health conditions.

See also

• COVID-19 vaccine
• COVID-19 pandemic
• SARS-CoV-2

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!